<DOC>
	<DOCNO>NCT00575887</DOCNO>
	<brief_summary>The purpose study evaluate efficacy temozolomide protract schedule , standard 5-day temozolomide regimen patient recurrent progressive high grade glioma .</brief_summary>
	<brief_title>Efficacy Protracted Temozolomide Patients With Progressive High Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patient age &gt; 18 year old Histopathological diagnosis high grade glioma ( anaplastic astrocytoma anaplastic oligodendroglioma anaplastic oligoastrocytoma glioblastoma multiforme ) Progression standard dose ( D15/28 day ) temozolomide either recurrence adjuvant treatment approve Magnetic Resonance imaging Karnofsky Performance Status scale &gt; /=50 ( due brain pathology ) Adequate hematological , renal hepatic function Patients willing participate study signing inform consent Karnofsky Performance Status scale &lt; 50 Female patient pregnancy suspicion pregnancy . Patients fertility warn appropriate contraception study Patients suitable followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Temozolomide</keyword>
	<keyword>Brain Tumor , Recurrent</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>